Abstract 4913
Background
Patients with carcinoma prostate undergo rapid decline in bone health as measured by bone mineral density in the first 6 to 12 months of treatment with androgen deprivation. The WHO has developed the FRAX (Fracture Risk Assessment) Tool to predict long-term risk of major fractures and hip fracture. Guidelines are available for managing therapy related osteoporosis. This study is to characterize the risk (based on the FRAX tool) and management on the basis of guidelines in view of non-availability of bone matrix density assessments on basis of DEXA Scan.
Methods
A retrospective analysis of 196 consecutive patients receiving LHRH agonists at a single practice for the period of 2010 to 2018 was done. Data was collected after IRB clearance and included demographics, medical history, treatment history, history of ADT, bone health and its management. 10y fracture risk was calculated using the FRAX tool. Descriptive statistics were used for demographic analysis and to characterise the management of bone health. Paired t-Test was used to compare 10y fracture pre and post ADT.
Results
A total of 196 patients were seen. The mean age was 65.5y. 36% patients had Stage II disease and 56% had Stage III disease. All patients had PSA >10 and a Gleason Score >7 and Life expectancy <10y. 97% patients received LHRH agonists for a mean period of 13.8 + 18.1 months. 57% patients had >2 Risk for osteoporosis. Counselling for adverse effect of ADT and bone side effects was seen in 20% of patients. Bone health assessment was not available for 75% of patients. Bisphosphonate therapy was seen in 3% of patients. The risk of sustaining a major fracture increased from 26% to 34% (P < 0.001) on initiation of ADT. The risk of sustaining a hip fracture rose from 12% to 20%. Guidelines was followed for DEXA Scan, Calcium supplements and Vitamin D in 22%, 15%, and 8% respectively.
Conclusions
In addition to predisposing factors of osteoporosis, ADT increases risk of fracture in patients with ca prostate. There is room for improvement by increasing health literacy in multi-disciplinary team and Care providers. This is the first paper of its kind in developing countries including quality practice audit.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
G S Bhattacharyya.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2831 - Interleukin-6 as a Predictive Marker for Early Response to Induction Chemotherapy in Acute Myeloblastic Leukaemia
Presenter: Salah Khallaf
Session: Poster Display session 1
Resources:
Abstract
6014 - Impact of FLT3-ITD mutation on post-transplant outcome of adult AML is modified by the concomitant NPM1 mutation and pre-transplant remission status: A report from Taiwan Bone Marrow Transplant Registry (TBMTR)
Presenter: Su-peng Yeh
Session: Poster Display session 1
Resources:
Abstract
2914 - Efficacy endpoints studied in clinical trials for early-onset leukaemia
Presenter: Dylan Said
Session: Poster Display session 1
Resources:
Abstract
4691 - High triglyceride is a major risk factor of DIC and differentiation syndrome in acute promyelocytic leukemia
Presenter: Tomohiro Yamakawa
Session: Poster Display session 1
Resources:
Abstract
4395 - DREAMM 4: A Phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)
Presenter: Suzanne Trudel
Session: Poster Display session 1
Resources:
Abstract
2808 - A Phase 1 Study of HMPL-523, a Selective Oral Anti-Spleen Tyrosine Kinase Inhibitor, in Patients with Relapsed or Refractory Lymphoma
Presenter: Nathan Fowler
Session: Poster Display session 1
Resources:
Abstract
4403 - A Phase 1 Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Patients with Relapsed or Refractory Lymphoma
Presenter: Jonathon Cohen
Session: Poster Display session 1
Resources:
Abstract
3357 - A global patient-driven Facebook study in a very rare sarcoma: Health-related quality of life in Epithelioid Hemangioendothelioma (EHE) patients
Presenter: Marije Weidema
Session: Poster Display session 1
Resources:
Abstract
2475 - Qualitative study of patients’ experiences of living with and beyond a soft tissue sarcoma diagnosis: the impact of sarcoma specialist services
Presenter: Ana Martins
Session: Poster Display session 1
Resources:
Abstract
2640 - Health-related quality of life issues of patients affected by desmoid-type fibromatosis; experiences from two countries
Presenter: Milea Timbergen
Session: Poster Display session 1
Resources:
Abstract